Live
FierceBiotechTraws defers midphase flu study after negative regulatory reviewLabiotechNew names, new narratives: Why biotechs decide to rebrandPharmaVoiceThe biotech market is rebounding. So where are the executive jobs?FierceBiotechSoligenix axes lymphoma program after phase 3 setback, mulls M&A optionsFierceBiotechBeyond Rigid Platforms: Adaptive Adenoviral Platform De-Risks Development to GMPFierceBiotechHow NEC's AI and oral delivery system are redefining personalized cancer therapyEndpoints NewsLilly puts its stamp at #EHA26 with Jaypirca combo data in CLL, first clinical data from Ajax buyoutBioPharma DiveCeliac disease is entering a new era of therapeutic innovationBioPharma DivePlanning a successful pivot from lab to clinicScience Daily BiotechScientists turned red lettuce green and something surprising happenedEndpoints NewsHMNC Brain Health raises $50M Series B to advance two depression drugseLifeExposure to false cardiac feedback alters pain perception and anticipatory cardiac frequency
This story is not available in the archive.